Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Sequent Medical said it raised a Series D round worth $20 million from its slate of previous investors, led again by Delphi Ventures.
Domain Associates, US Venture Partners and Versant Ventures also participated, Sequent said. Read more
Abiomed said it won CE Mark approval in the European Union for its Impella RP heart pump, designed to assist the heart’s right ventricle in heart failure patients.
Like its flagship Impella device, the Impella RP is threaded to the heart through the femoral artery. But, unlike previous Impella models designed for the heart’s left ventricle, the Impella RP is designed to access the heart’s right ventricle via the vena cava. Read more
Breast cancer experts are calling for a fresh look at routine mammography, warning that screening may not save lives and may instead lead to risky overdiagnoses.
In a pair of editorials published in the Annals of Internal Medicine, researchers cited extensive new data that suggests that mammograms provide no life-saving benefit compared with regular breast exams and routine care. The new findings, taken from two 25-year Canadian National Breast Screening Studies, cast doubt on older trials that made a strong case for routine mammography. Read more